Thymosin Alpha-1
A thymus-derived immune-modulating peptide, approved abroad as Zadaxin for hepatitis, that reshapes rather than simply boosts immune response.
Thymosin alpha-1 (Tα1) is a 28-amino-acid N-terminally acetylated peptide corresponding to the N-terminal fragment of prothymosin alpha, first isolated from thymic tissue by Allan Goldstein's laboratory in the 1970s. Marketed as Zadaxin by SciClone, it is approved in roughly 35 countries as an immune adjuvant for chronic hepatitis B and C and in some markets for cancer chemotherapy support and severe immunodeficiency. It acts as a pleiotropic immune modulator through Toll-like receptor signaling, dendritic cell maturation, and T-cell/NK-cell activation rather than as a blunt immune stimulant. It is not FDA-approved in the United States, where it circulates as a research compound and off-label immune-support peptide.
Class
Synthetic 28-amino-acid N-terminally acetylated thymic peptide
Half-life
~2 hours in plasma (2–3 hours reported); biological effect extends beyond plasma half-life via downstream cellular activation
Routes
Subcutaneous, Intravenous (clinical settings)
Category
Immune & Mitochondrial
Researched benefits
What it's studied for
Hepatitis B adjunct therapy
The strongest evidence lane: Tα1 is approved in ~35 countries as an adjunct to antiviral/interferon regimens for chronic hepatitis B, with Phase 3 trials reporting sustained virological response rates of 25–40% as monotherapy and higher in combination. A multicenter RCT combining Tα1 with entecavir in HBV-related compensated cirrhosis was well tolerated and showed a tendency to inhibit hepatocellular carcinoma development.
Immune modulation, not blunt stimulation
Tα1 shifts immune response patterns rather than amplifying all activity — driving dendritic cell maturation, Th1 polarization, and balanced cytokine signaling. This selective, context-dependent modulation underlies its use in settings where straightforward immune activation would cause harm.
T-cell and NK-cell enhancement
Promotes differentiation of T-cell precursors, raises CD4+/CD8+ counts and improves the CD4/CD8 ratio in lymphopenic and aging states, reduces T-cell exhaustion markers in chronic viral infection, and boosts natural killer cell cytotoxicity important for antiviral and tumor surveillance.
Vaccine response enhancement
Used as an immune adjuvant to improve response to influenza and hepatitis B vaccines in immunocompromised patients — such as the elderly, dialysis patients, and hepatitis B vaccine non-responders — by enhancing antigen presentation and T-cell priming.
Cancer immunotherapy adjunct (frontier)
An emerging area: a 2025 hepatocellular carcinoma retrospective combining Tα1 with lenvatinib and sintilimab reported a real survival signal (median OS 16 vs 11 months), and preclinical work shows IL-15 plus Tα1 reduces senescent hepatic CD8+ T cells. Immunosenescence and PD-1 combination work is where modern literature is drifting; melanoma and some other oncology trials have been mixed or negative.
Post-viral and aging immune support (extrapolated)
Widely used off-label for long COVID, chronic viral reactivation (EBV, HHV-6), and age-related thymic decline. Reports are modest but consistent among users with documented immune dysregulation, while healthy users tend to report less — as expected of an immunomodulator. Rigorous trials for these community uses are lacking.
Favorable, well-documented safety profile
Among the cleanest safety records of any bioactive peptide: decades of approved clinical use across many countries with minimal adverse events, no significant organ toxicity, and no clear autoimmunity signal at therapeutic doses.
Mechanism
How it works
Thymosin alpha-1 does not act through a single canonical receptor. Its most characterized mechanism is engagement of pattern-recognition receptors — primarily Toll-like receptor 9 (TLR9) and TLR2 — on dendritic cells, monocytes, and plasmacytoid dendritic cells. This activates MyD88- and TRIF-dependent signaling, driving NF-κB and IRF3/IRF7 activation, dendritic cell maturation with MHC II and costimulatory-molecule upregulation, type I interferon (IFN-α/β) production, IL-12 output that polarizes T cells toward Th1, and enhanced antigen presentation.
On the adaptive side, Tα1 promotes differentiation of T-cell precursors from thymic and extra-thymic origins, increasing CD4+ and CD8+ counts in lymphopenic states, improving the CD4/CD8 ratio in aging or immunocompromised patients, enhancing proliferative responses to antigens, and reducing T-cell exhaustion markers in chronic viral infection. It shifts cytokine balance toward a Th1 profile (IFN-γ, IL-2) in Th2-dominant states while providing complementary rebalancing in Th1-dominant states. It also enhances natural killer cell cytotoxicity and IFN-γ production, and modulates regulatory T-cell function in a context-dependent way — reducing Treg dominance in chronic infection or cancer while preserving Treg balance in autoimmune-prone settings.
Tα1 modulates inflammatory cytokines rather than uniformly suppressing or amplifying them: it lowers TNF-α and IL-6 in inflammatory contexts, raises IL-2 and IFN-γ in antiviral contexts, and tunes IL-10 and TGF-β for balanced responses. It also exerts anti-apoptotic and cytoprotective effects, reducing lymphocyte apoptosis and protecting dendritic cells during severe infection, thereby preserving immune architecture.
Pharmacokinetically, subcutaneous Tα1 reaches peak plasma concentration 1–2 hours post-dose with an elimination half-life of roughly 2–3 hours, cleared primarily by renal filtration. It has no oral bioavailability and requires injection. Importantly, its biological effect extends well beyond plasma half-life because downstream cellular activation — dendritic cell maturation over 24–48 hours and T-cell effects over days — outlasts the peptide's presence. Effects do not follow a simple linear dose-response, which is why the clinical standard of 1.6 mg twice weekly has been optimized over decades of trials.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
Typical: a 10 mg lyophilized vial reconstituted with 2 mL bacteriostatic water yields 5 mg/mL. On a U-100 insulin syringe at that concentration, 1 unit (0.01 mL) = 50 μg, so 18 units = 900 μg, 20 units = 1 mg, and 32 units = 1.6 mg (standard dose). Alternatives: 10 mg + 1 mL = 10 mg/mL (1 unit = 100 μg; 16 units = 1.6 mg) for minimal injection volume, or 10 mg + 4 mL = 2.5 mg/mL for fine titration. Dribble the water down the vial wall, swirl gently (do not shake) until the pellet dissolves into a clear colorless solution, then refrigerate.
Beginner
- Dose
- 1.6 mg
- Frequency
- Twice weekly (e.g. Monday and Thursday)
- Timing
- Morning or evening; the 3–4 day interval matters more than time of day
- Duration
- 8–12 week courses, then a 4-week break; repeatable quarterly
- Route
- Subcutaneous
Standard immune-support protocol matching the approved Zadaxin schedule. Rotate injection sites (abdomen, flank, thigh). Start at the standard dose — there is no clear benefit to higher per-injection doses.
Intermediate (Daily acute support)
- Dose
- 900 μg
- Frequency
- Daily
- Timing
- Morning preferred
- Duration
- 4–8 weeks, then transition to twice-weekly 1.6 mg maintenance or discontinue
- Route
- Subcutaneous
Used for post-infection recovery, long COVID, or intensive immune support. Both daily 900 μg and twice-weekly 1.6 mg are evidence-supported; there is no clear proof daily is superior for long-term use.
Vaccine response enhancement
- Dose
- 1.6 mg
- Frequency
- Twice weekly
- Timing
- Start ~2 weeks before planned vaccination, continue 4 weeks after
- Duration
- ~6 weeks around vaccination
- Route
- Subcutaneous
For immunocompromised patients — e.g. flu vaccination in the elderly or dialysis patients, hepatitis B vaccination in non-responders.
Advanced (Chronic / clinical, supervised)
- Dose
- 1.6 mg twice weekly, or 900 μg daily; intensive contexts up to 1.6 mg daily for 4–8 weeks
- Frequency
- Twice weekly to daily
- Timing
- Day-of-week consistency prioritized
- Duration
- 3–12 months (chronic hepatitis B, long COVID with immune dysregulation, chronic viral reactivation)
- Route
- Subcutaneous
Extended courses for chronic conditions ideally under clinician supervision. Cancer immunotherapy adjunct use requires oncology direction and must never be self-directed. Long-term continuous use beyond 1 year is uncharacterized in large studies.
- Effects are subtle and accrue over 4–8 weeks — do not expect dramatic acute effects from individual doses.
- Do not exceed 1.6 mg per injection or dose three-plus times weekly at 1.6 mg without clear indication; higher cumulative exposure adds cost without proportional benefit.
- Under-dosing (500 μg or less) may fail to reach effective tissue concentration unless specifically indicated.
- Tα1 is not directly antiviral — it works as immune support over days to weeks, not as an acute anti-flu agent.
- Optional but recommended monitoring for longer courses: baseline CBC with differential, CD4/CD8 ratio, NK cell function, CRP, ferritin, and 25-hydroxyvitamin D, repeated at 8–12 weeks.
- Optimize non-peptide foundations first (sleep, nutrition, vitamin D, zinc); these are often the actual limiting factors in non-response.
- Lyophilized vials are stable 24+ months refrigerated or frozen; reconstituted solution is stable 4–6 weeks refrigerated at 2–8°C and must not be frozen or exposed to light.
- Avoid during active high-dose corticosteroid therapy (pharmacologically opposed) and in transplant recipients without specialist approval.
Evidence
Research & clinical studies (2)
Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study
Combination therapy with thymosin alpha-1 plus entecavir was well tolerated and showed a tendency to inhibit hepatocellular carcinoma development over 52 weeks compared with entecavir monotherapy in HBV-related compensated cirrhosis (n=690).
PMID 30063860IL-15 Plus Thymosin α1 Reduces Senescent Hepatic CD8(+) T Cells in Hepatocellular Carcinoma via PI3K/AKT Suppression
Combining IL-15 with thymosin alpha-1 synergistically reduced senescent CD8+ T cells in hepatocellular carcinoma by suppressing overactive PI3K/AKT signaling, restoring anti-tumor immunity and prolonging survival in an aged mouse model.
PMID 41883056Combinations
Stacking & blends
Immune Support Stack (Tα1 + LL-37)
Broad-spectrum immune support across adaptive and innate arms
Combines Tα1's T-cell maturation and adaptive immune enhancement with LL-37's antimicrobial peptide activity and innate immune modulation, targeting both immune arms through complementary mechanisms — favored for chronic infection contexts where host immunity plus direct antimicrobial coverage is desired.
Comprehensive Wellness Triple (Tα1 + BPC-157 + TB-500)
Immune competence plus tissue repair and recovery
Tα1 twice weekly for immune modulation, BPC-157 250 μg twice daily and TB-500 2–2.5 mg twice weekly for tissue repair and actin dynamics. Tα1 and TB-500 are distinct peptides despite shared thymosin naming and can be stacked without interaction.
Longevity / Aging Immunity Stack (Tα1 + Epithalon)
Immune-preservation and longevity-oriented support in aging
Pairs Tα1's rebuilding of thymic immune function (declining with age-related thymic involution) with Epithalon's longevity positioning; often extended with BPC-157 and lifestyle factors. Mechanistically plausible for immune support in aging, though not proven to extend lifespan.
Long COVID / Post-Viral Support
Immune support in post-viral syndromes with documented dysregulation
Tα1 layered with complementary agents such as low-dose naltrexone, NAC, and mitochondrial support in long COVID protocols; realistic framing is that Tα1 supports immune function alongside other interventions rather than curing the condition.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Organ transplant recipients on maintenance immunosuppression (risk of rejection)
- Active hypersensitivity to Tα1 preparations
- Pregnancy (no adequate safety data)
- Breastfeeding (no data)
- Acute hyperinflammatory states (severe cytokine storm, uncontrolled late-phase sepsis) — specialist assessment required
- Poorly controlled autoimmune disease (lupus, RA, MS, Hashimoto's) — risk of flare, only under specialist supervision
- Active hematologic malignancy (requires oncology direction)
- Concurrent high-dose systemic corticosteroids or cytotoxic chemotherapy (pharmacologically opposed or complex interactions)
Tα1 has one of the cleanest safety profiles among bioactive peptides — 45+ years of clinical use in hundreds of thousands of patients with no significant organ toxicity and no clear autoimmunity signal at therapeutic doses. Drug interactions matter: immunosuppressants and high-dose corticosteroids pharmacologically antagonize it, interferons are generally synergistic, and checkpoint inhibitors are potentially synergistic (active research). Stop use for signs of allergic reaction, persistent severe injection-site reaction, new or worsening autoimmune symptoms, a new cancer diagnosis, or confirmed/suspected pregnancy. It is not explicitly WADA-prohibited but appears on some monitored lists — competitive athletes should verify current status.
FAQ
Thymosin Alpha-1 — common questions
What does Tα1 actually do to my immune system?
It is best understood as an immune modulator rather than a booster. It engages Toll-like receptors (mainly TLR9 and TLR2) on dendritic cells, driving dendritic cell maturation, enhanced T-cell differentiation, improved NK-cell function, and balanced cytokine patterns. Practically this means better response to viral infection and improved vaccine response in immunocompromised states — it shifts immune response toward more effective, balanced activity rather than broadly amplifying inflammation.
Is Tα1 the same as thymosin beta-4 (TB-500)?
No. Despite the shared thymosin naming they are completely different peptides. Tα1 is a 28-amino-acid immune-modulating peptide from the thymus. TB-500 (thymosin beta-4) is a 43-amino-acid peptide with actin-regulating and tissue-repair functions used mainly for healing and recovery. They can be stacked without interaction, but their indications differ.
How long does it take to feel Tα1 working?
Most effects are subtle and emerge over 4–8 weeks rather than within hours or days. There is no acute noticeable sensation from individual doses. What improves over weeks: fewer and shorter infections, better recovery, improved energy in chronic-fatigue contexts, and better lab markers such as the CD4/CD8 ratio and vaccine response. Expecting dramatic acute effects leads to disappointment.
Is Tα1 FDA-approved, and do I need a prescription?
It is not FDA-approved in the US, though it is approved as Zadaxin in 35+ countries, mostly for chronic hepatitis B and C. In December 2024 the FDA's PCAC voted against 503A compounding inclusion, effectively closing the routine US compounding pathway. Domestically it circulates as a research chemical for laboratory use; brand-name Zadaxin is prescription-only where approved abroad.
Will Tα1 trigger autoimmune disease?
There is a theoretical concern since it activates immune response, but 45+ years of clinical use in hundreds of thousands of patients has not shown a clear autoimmunity signal. People with pre-existing autoimmune disease (lupus, RA, MS) should discuss with their rheumatologist first, as flares are theoretically possible. In healthy users the risk appears very low but not zero — stop and consult a clinician if new unexplained joint pain, rashes, or fatigue patterns emerge.
Can Tα1 help with long COVID?
There is emerging evidence of benefit in a subset of long COVID patients, particularly those with documented immune dysregulation (low lymphocyte counts, skewed CD4/CD8 ratios, viral reactivation). Observational studies and small trials report improvements in fatigue and immune function, but rigorous large trials are still needed. It is not a cure and works best as part of broader treatment including graded activity, sleep, and nutritional support.
Is daily or twice-weekly dosing better?
Both are supported for different contexts. Twice-weekly 1.6 mg (the approved Zadaxin regimen) is best for long-term maintenance and most chronic indications and has the most evidence. Daily 900 μg is used for more intensive acute or intermediate-term support such as post-viral recovery. There is no clear evidence daily is superior for long-term use, and the higher total dose adds cost without proportional benefit for most indications.
Can I use Tα1 alongside chemotherapy or cancer treatment?
This is strictly an oncology-supervision question — never self-direct Tα1 alongside cancer treatment. There is research interest in combining it with checkpoint inhibitors (potential synergy) and some historical use with chemotherapy, but timing, dosing, and combination choices significantly affect outcomes, and it could theoretically help or hurt depending on context. Only integrative oncology clinicians familiar with both Tα1 and your specific cancer should guide this.
